{"name":"Biotie Therapies Inc.","slug":"biotie-therapies-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BTT1023","genericName":"BTT1023","slug":"btt1023","indication":"Rheumatoid arthritis","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"SYN117 80 mg","genericName":"SYN117 80 mg","slug":"syn117-80-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"BTT1023","genericName":"BTT1023","slug":"btt1023","phase":"phase_2","mechanism":"BTT1023 is a monoclonal antibody that blocks the CC chemokine receptor 2 (CCR2) to reduce inflammatory cell recruitment and immune activation.","indications":["Rheumatoid arthritis","Inflammatory bowel disease"],"catalyst":""},{"name":"SYN117 80 mg","genericName":"SYN117 80 mg","slug":"syn117-80-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPVTB3cUxJVUdQa2VEZ0VBV0Z6WnZKVjdLWGdIbG1oYXRLbC1uVDBXdVhQdDEyOXVDQmt3QnRkbDdabDBTNUplbldDLUVrRmVSeGtKdUg1dXRPaHEteVhmaG50YVhYR3haTnVqWFBPSE4zeWtwZjZxS0NGSlRkMlpuZ2dfVlVWTEtPUWtONFlBRTRrX25ZSWNFS3RVakRtWGNlUVd5OFBKTGZqa3pLdnhfV2NOZEM?oc=5","date":"2025-10-25","type":"trial","source":"Technology Networks","summary":"The Challenges of Conducting Rare Disease Clinical Trials - Technology Networks","headline":"The Challenges of Conducting Rare Disease Clinical Trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1xV2tSR1YzODFHa0hsTVBscmF0dEk0QnhOSG9WMG9UMVpOWHZWQjV1dUFMTmFXTGZGRDdNUUplSDA3c2VyMzVyWEdUVEVmZE1lajB2a0w3bHBjeXBJTmU3T0l3REdYSm40ZEFWYXYweEIwUTIzeG1wanVINHZPdw?oc=5","date":"2024-07-11","type":"pipeline","source":"Yahoo Finance","summary":"Merz wins $185m bid for bankrupt Acorda assets and increases US workforce by 50% - Yahoo Finance","headline":"Merz wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPaDA0S1JZd2R6MTI1YUw0ejFreUllRDRNbFJQaUFFdUVCcUs1QWhJSzNSMnpzTFVlUktQM1Y2YlYxZFhDM1ZKbW5sUi1XMVBOWWJ4YXhfSlByRnNzNFpVM3FqaUE3RkJaQjJZSk5Md2pyenJrTVJqdm9PZmdFV2pBSkppbFVfRGhXa19IQWZXakx4RzN3Sndxcl81WQ?oc=5","date":"2024-04-04","type":"pipeline","source":"thestreet.com","summary":"Essential drug company to liquidate in Chapter 11 bankruptcy - thestreet.com","headline":"Essential drug company to liquidate in Chapter 11 bankruptcy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQWG40UG8yM3RwQXcwb09rUVBOZUtyeTNhSGN1LWJSaVA1RHNmaXhFd3c3ZXNJcFZ5aFJ4QVh5YkhpVnVnZmxXV0V3TzlubGRsSmlvSTNqVjc4NlRPR0tHeVowS1VPalVZeElpVkEzX2oxbXY1SU5QNW1hekJrOTFMdkN5dHg3ZVJTSmFzWnB5eEZBWENSMXBkLU9kNExkZlcwLWxn?oc=5","date":"2024-04-02","type":"pipeline","source":"Pharmaceutical Technology","summary":"Merz makes a $185m bid for assets from bankrupt Acorda - Pharmaceutical Technology","headline":"Merz makes a $185m bid for assets from bankrupt Acorda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPVXkyRE55NWJxdzVZRUVCTFhoN3NpUkJnQTZuNDRsVnhER241ZVZuSDN5a0hoRTFqeURVeklJcnFITXo2OUZMbUY1ZWV0ZFJ4cUJHOE1oYndvTGdEN0pNbWdvY2pSUHRGX3hmTFlvNDlKZmR3TEdPdTZRZnF5TldKV1MwdTNlVWxKQVphQ3UxcEd3djJUblBrWGo5WHNRXzZOT2hJVHBrNllxVzV0U1hOaTEwZGFQQ2hGT1NSN0JSaTJ1RTRiSndzazlMN0w?oc=5","date":"2022-12-08","type":"pipeline","source":"European Medical Journal","summary":"Tailoring Motor Fluctuation Treatment: Beyond Levodopa Dose Adjustment - European Medical Journal","headline":"Tailoring Motor Fluctuation Treatment: Beyond Levodopa Dose Adjustment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOU0VmQk9kRnJZcWc1ZWE2ZUZXaEctNW5RRDk3YnpyVlZBRVZfUG9ha2VRR3JhclBDVTk1UzB5ekxPOUNISW1rdzVUVG9HbG54M0w1alRETmQ3RVpLTDFNRkV2TW9yVUlleEEzX1pnLXEtNG83a2d6ZThLZW83QkNrMWpWb2p0SmPSAYwBQVVfeXFMT3gzSElZSHhGVXE0TFpMOVV1elAzQ0gtZzlfRVgzRkVLSHhOeXZoMVNJeFZiOXhNSVZEMnFEVUgxZGRNdFNTVDA2b1d1UUN1VjlBcWNvRS11b1dCVl9LTTM4SjdaU0hJZXJLclRsOFAtQmJlYlRvN2x4UnB4aUhGaV9UMUFwSzJkdDQyZzY?oc=5","date":"2021-04-09","type":"deal","source":"Businessday NG","summary":"Neurelis, Biote partner on product expansion - Businessday NG","headline":"Neurelis, Biote partner on product expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNRTVENXh0QktIRU5DMXJEWFRMMHN1bU84eUFNX0lFWlozM09wcW9wQUQ4NmlnblNMdjFXYTNGLXR3UmN2NUJvNlYySVJqd083MVlvakRlam11SHpScWRySk50VDRDWHZ1WHNJVWMyaVJ2NjJBQUVOU1pqNF9UU0l1Nk92WGtZb2I2ZmJXeF9lZ3ZiOXNfazNaQThQeTUxT0hDSG9qcXdfcG0tMG90ZlMzWnBzeWk?oc=5","date":"2016-01-19","type":"deal","source":"BioPharma Dive","summary":"Biotech Acorda buys Finnish firm Biotie & its Parkinson’s candidates for $363M - BioPharma Dive","headline":"Biotech Acorda buys Finnish firm Biotie & its Parkinson’s candidates for $363M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiP0FVX3lxTE1la3BLN2s2anA1a3NUYklkcmRQM2hzMXkweHhXTXpRLW9vWlJNcEw5MGxWRlh5VWpVRWJSaWZSYw?oc=5","date":"2013-03-01","type":"regulatory","source":"Yle","summary":"EU approves Finnish drug aimed at curtailing alcohol abuse - Yle","headline":"EU approves Finnish drug aimed at curtailing alcohol abuse","sentiment":"positive"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}